Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Effects of Pegcetacoplan to Slow Progression of GA Increase Over Time: Dr Eleonora Lad
February 10th 2023For patients with geographic atrophy (GA) taking pegcetacoplan, the drug’s effect to slow disease progression increases over time as patients take the drug, said Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Read More
Angiogenesis Meeting to Highlight Latest in Technology, Translational Research, Clinical Trials
February 8th 2023The Angiogenesis, Exudation, and Degeneration 2023 meeting will be held virtually with a program focused on understanding and treating neovascular, exudative, and degenerative diseases of the eye.
Read More
Dr Eleonora Lad Highlights the Importance of Upcoming Pegcetacoplan Results
February 8th 2023With no treatment options currently available for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), pegcetacoplan could fill a huge unmet need, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Read More
Dr Timothy Murphy Discusses How COVID-19 Has Affected Lung Cancer Screening
January 26th 2023Timothy Murphy, MD, FACP, practice president of Rocky Mountain Cancer Centers, spoke with The American Journal of Managed Care® about the effect of the COVID-19 pandemic on screening for lung cancer.
Read More
CARG Chemotherapy Toxicity Tool Helps Patients Understand Risks, Says Dr Alonso V. Pacheco
January 21st 2023Patient quality of life can be improved through shared knowledge between doctors and patients in cancer care using the Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Tool calculator, which Rocky Mountain Cancer Centers piloted, explained Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
Read More
New immunotherapies are changing the shape of oncology care, but there is also a need for a system that provides these high-quality therapies to the patients most likely to benefit from them. This might mean doing an assessment and a deeper dive into patient functional status, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
Read More
Data Can Be Used to Improve Patient Decision Making and Address Disparities, Says Dr Ken Cohen
January 14th 2023Initiatives to address social determinants of health are likely to positively change the health care landscape, and better patient education can contribute to more favorable care choices says Ken Cohen, MD, director of translational research for Optum Care.
Read More
Dr Alonso V. Pacheco Discusses a Tool to Measure Chemotherapy Toxicity for Elderly Patients
January 13th 2023A tool to measure chemotherapy toxicity from the Cancer and Aging Research Group can help determine emergency department visits or hospitalization risk, especially for elderly patients, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.
Read More
Dr Ken Cohen Offers Possible Solutions to Reducing Wasteful Health Care
January 12th 2023Creating new incentive models and transparently sharing data in a way that changes behaviors are 2 ways to reduce low-value care in the health care system, explains Ken Cohen, MD, director of translational research for Optum Care.
Read More
Impact of Patient Factors on Developing AML After MDS or CML; Ponatinib in Highly Resistant CP-CML
January 7th 2023Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.
Read More
FDA’s Lecanemab Approval Will Raise Pricing, Access Challenges, Says Dr Alvaro Pascual-Leone
January 6th 2023The FDA’s approval of lecanemab for Alzheimer disease is very important, but there will remain significant challenges around pricing and access that will need to be addressed to deliver on the promise the therapy actually represents, said Alvaro Pascual-Leone, MD, PhD, of Harvard Medical School.
Read More
PBMs Announce 2023 Coverage Plans for Adalimumab Biosimilars
January 1st 2023The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved interchangeable biosimilar.
Read More
Abstracts Highlight the Efficacy of BCL-2 Inhibitors in AML and CLL
December 29th 2022Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
FDA Approves Bispecific Antibody Mosunetuzumab for R/R Follicular Lymphoma
December 23rd 2022The approval makes mosunetuzumab the first in its class approved to treat follicular lymphoma and comes shortly after data from a phase 2 trial was presented at the annual meeting of the American Society of Hematology.
Read More
Aligning Payers and Providers for Value-Based Cancer Care Payments
December 9th 2022Lucy Langer, MD, MSHS, national medical director, oncology and genomics, MSHS, national medical director, oncology and genomics, UnitedHealthcare, discussed value-based contracting at the IVBM® session October 5, 2022.
Read More
Dr Kalin Clifford Outlines Research Into Alternative/Complementary Therapies for Dementia
December 7th 2022There is new data coming out on complementary and alternative therapies for dementia, including supplements, mindfulness techniques, exercise, music therapy, and more, said Kalin Clifford, PharmD, BCGP, BCPS, FASCP, associate professor, Geriatrics Division, Texas Tech University Health Sciences Center, Jerry H. Hodge School of Pharmacy.
Read More
Some of the latest trends in the health-system pharmacy space are ones that have already been around for a while, and organizations will need to understand how to address them at the local level, explained Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, executive vice president and provost at Oregon Health and Science University.
Read More